KB Home and the Well Living Lab Partner for Groundbreaking Multiyear Healthy Home Research Project

KB Home and the Well Living Lab Partner for Groundbreaking Multiyear Healthy Home Research Project

The Well Living Lab, founded as a collaboration between Delos® and Mayo Clinic, is the first laboratory exclusively focused on researching how indoor environments can improve human health and well-being.

KB Home (NYSE: KBH) and the Well Living Lab today announced a multiyear research project. The Well Living Lab, founded as a collaboration between Delos and Mayo Clinic, is dedicated to the advancement of knowledge to transform indoor environments and improve human health and well-being. The research project will focus on accelerating new discoveries by migrating findings from the Well Living Lab’s research to real-world assessments in partnership with KB Home. This is an important step toward improving public awareness of the impact of the home environment on physical health, mental stress and productivity. It is also an opportunity to advance these new discoveries in a home environment to improve personal comfort, resiliency and overall wellness.

The KB Home and the Well Living Lab research project will span three phases:

  • Phase 1: Launching in February 2021, KB Home and the Well Living Lab will educate homebuyers about current healthy home technologies and products at a new KB community model home in Phoenix near the Mayo Clinic Arizona campus.
  • Phase 2: KB Home will build a dedicated “test laboratory” home for the Well Living Lab to conduct evidence-generating research about the impact of indoor environments on the health of occupants.
  • Phase 3: KB Home and the Well Living Lab will begin pilot studies in partnership with homeowners in the Phoenix area to validate research outcomes to create healthier indoor environments and gain insight on how to best bring them to consumers.

“The Well Living Lab draws upon the expertise of our building, health and behavioral scientists to conduct human-focused studies in both simulated and real-world settings,” said Dr. Win Shen, a Mayo Clinic cardiologist and advisor to the Well Living Lab on its Healthy Home research project. “There are many benefits to this multiyear project that will allow the Well Living Lab to bring its research out of the lab and into real homes. By conducting studies with KB Home, we can gather valuable data to improve the places where people live, work and play.”

Well Living Lab Managing Director and Delos Senior Vice President Barbara Spurrier added, “The Well Living Lab, in partnership with KB Home, is committed to translating and applying its discoveries to improve human health and generate tangible contributions to society.”

KB Home has been a strong champion for many years of the key role homebuilders can play in constructing healthier homes. The partnership between KB Home and the Well Living Lab further reinforces the homebuilder’s commitment to promoting health and wellness through sustainable homebuilding.

“We made the commitment almost two decades ago to building sustainable homes that can support the health of their residents,” said Jeffrey Mezger, KB Home’s Chairman, President and CEO. “Well before the current pandemic, we saw we could offer affordable homes that can make a positive impact on what we value most but can’t buy: our health. We’re proud to lead our industry in focusing on improved indoor air quality and other wellness features and honored to partner with the Well Living Lab on this multiyear research project directed at advancing the future of healthier homes.”

Nearly 20 years ago, the company built its first ENERGY STAR® certified new home. Today, every KB home is designed to be ENERGY STAR certified and deliver an enhanced indoor environment thanks to quality construction techniques and materials as well as high performance ventilation systems that regularly introduce fresh outdoor air. Additionally, the company incorporates design features guided by the Environmental Protection Agency’s (EPA) Indoor airPLUS standards, including low- or zero-VOC products in carpeting, paint, insulation and cabinetry, and comprehensive air sealants to significantly reduce drafts, moisture, dust and pollen as well as antimicrobial door handles and touchless faucets to reduce the spread of germs.

KB Home is also a leader in advancing new technologies. In January 2019, the company debuted KB ProjeKt®: Where Tomorrow Lives™, a health-oriented concept home of the future that redefined the home as a “health hub.” In that same year, KB Home became the first U.S. homebuilder to offer the Delos DARWIN™ Home Wellness Intelligence platform in select communities, a powerfully integrated wellness system that monitors and calibrates the indoor home environment.

About KB Home

KB Home (NYSE: KBH) is one of the largest and most recognized homebuilders in the United States and has been building quality homes for over 60 years. Today, KB Home operates in 42 markets across eight states, serving a wide array of buyer groups. What sets us apart is how we give our customers the ability to personalize their homes, from homesites and floor plans to cabinets and countertops, at a price that fits their budget. We are the first builder to make every home we build ENERGY STAR® certified. In fact, we go beyond the EPA requirements by ensuring every KB home has been tested and verified by a third-party inspector to meet the EPA’s strict certification standards, which helps to lower the cost of ownership. We also work with our customers every step of the way, building strong personal relationships so that they have a real partner in the homebuying process and the experience is as simple and easy as possible. Learn more about how we build homes built on relationships by visiting kbhome.com.

About the Well Living Lab

The Well Living Lab, founded as a collaboration of Delos and Mayo Clinic in 2016, is dedicated to identifying how indoor environments impact human health and well-being. It conducts scientific research with human subjects in a simulated real-world environment and shares practical findings that can be applied to improving indoor spaces where people spent approximately 90 percent of their time. The lab has 5,500 square-feet of sensor-rich, reconfigurable space in downtown Rochester, Minnesota. Learn more about the contributions of the Well Living Lab at welllivinglab.com.

Craig LeMessurier, KB Home


[email protected]

Sarah Oslund, Well Living Lab


[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Research General Health Architecture Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Construction & Property Science Urban Planning Building Systems Landscape Health Interior Design



PolarityTE Receives Allowance for First U.S. Patent

PolarityTE Receives Allowance for First U.S. Patent

Allowance of U.S. Patent Application No. 14/954,335 Further Bolsters PolarityTE’s Patent Portfolio

SALT LAKE CITY–(BUSINESS WIRE)–PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Application No. 14/954,335. This is the Company’s first patent allowance in the United States. This patent application, which was originally filed on November 30, 2015, covers methods of making compositions for regenerating functional skin tissue using the Company’s minimally polarized functional unit (MPFU) technology.

The Company continues to prosecute additional patent applications in the United States and abroad related to its regenerative technologies and SkinTE®.

Internationally, the Company continues to build its patent portfolio. Patent Application No. 2017-530217 was also recently allowed in Japan. This Japanese application relates to compositions for regenerating functional skin tissue produced by methods utilizing MPFU technology. In addition, Singapore Patent No. 11201704502R was granted to PolarityTE on November 4, 2020, covering the same MPFU compositions as those patented in the United Kingdom.

Upon issuance of the allowed applications, PolarityTE will raise its patent portfolio to 7 granted patents. Patents have already been granted in the United Kingdom (Patent GB 2569056 B), Canada (Patent No. 2969707), Australia (Patent No. 2015355187), and New Zealand (Patent No. 733433).

David Seaburg, Chief Executive Officer, commented, “The allowance of PolarityTE’s first U.S. patent is an incredible accomplishment that demonstrates continued fundamental progress and execution as we work to build and protect valuable regenerative medicine assets, most notably SkinTE.” Mr. Seaburg continued, “This achievement is a testament not only to our technology, but also the tremendous efforts of our team led by Jennifer Burdman, our Chief Intellectual Property Officer, who was recently named one of the Top 25 Women Leaders in Biotechnology in 2020 by the Healthcare Technology report, as well as our Principal Patent Attorney, Mary Bram.”

Jennifer Burdman commented, “We are thrilled to see the USPTO allow this patent after careful consideration and diligence. This will be PolarityTE’s first U.S. patent and is a significant milestone in building out a robust U.S. patent portfolio.” Jennifer continued, “PolarityTE detractors have tried to use past USPTO office actions to create a false narrative regarding the Company and the patentability of its technology. We have consistently maintained that their narrative was not accurate, and now have the allowance of this application as further proof. We believe now as we always have that the Company’s technology works and the IP surrounding our technology is protectable.”

About PolarityTE®

PolarityTE is focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient’s own tissue and uses the patient’s own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic, and self-propagating product designed to regenerate the target tissues. PolarityTE’s innovative methods are intended to promote and accelerate growth of the patient’s tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.

About SkinTE®

SkinTE is a human cellular and tissue-based product derived from a patient’s own skin (autologous) intended for the repair, reconstruction, replacement, or supplementation of skin tissue. Aseptic surgical procedures and handling during skin harvest, wound preparation, and SkinTE deployment are mandatory.

SkinTE is currently marketed as a human cell, tissue, and cellular and tissue-based product regulated solely under Section 361 of the Public Health Service Act (PHS Act) and 21 CFR Part 1271 (i.e., as a 361 HCT/P). PolarityTE plans to file an investigational new drug application (IND) with FDA followed by a biologics license application (BLA) to have SkinTE regulated as a biologic under the federal Food Drug & Cosmetic Act and Section 351 of the PHS Act (i.e., as a 351 HCT/P), and will propose to FDA a plan for transitioning SkinTE from a 361 HCT/P to a 351 HCT/P.

Forward Looking Statements

Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “intend,” “plan,” “will,” “would,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to the impact of the COVID-19 pandemic and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.


Rich Haerle

VP, Investor Relations

PolarityTE, Inc.

[email protected]

(385) 315-0697

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Biotechnology Health Surgery



Whole Earth Brands, Inc. to Participate in the Canaccord Genuity 2020 Virtual AgriFood Tech Innovation Summit

CHICAGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Whole Earth Brands, Inc. (the “Company”) (Nasdaq: FREE), today announced that Chief Executive Officer Albert Manzone will present at the Canaccord Genuity AgriFood Tech Innovation Virtual Forum on Thursday, December 3, 2020 at 2:00 PM ET.

The live audio webcast will be accessible in the News & Events section on the Company’s Investor Relations website at investor.wholeearthbrands.com. An archived replay of the webcast will also be available shortly after the live event has concluded.

About Whole Earth Brands

Whole Earth Brands is a global platform of branded products and ingredients focused on the consumer transition towards healthier lifestyles, such as free from sugar, natural solutions, plant-based and clean label. Whole Earth Brands Inc. is one of the world’s leading manufacturers of zero/low sugar and calorie sweeteners as well as reduced sugar products with brands including Whole Earth®, Swerve®, Pure Via®, Equal®, and Canderel®. The Company’s branded product line Magnasweet® offers versatile masking agents, sweetness intensifiers and extenders and flavor enhancers. The company has a vision to expand its branded portfolio globally through investment opportunities in additional categories, with better for you clean label alternatives in the quest to “Open a World of Goodness®” to consumers and their families. For more information, please visit www.WholeEarthBrands.com.


Investor Relations Contact:

Whole Earth Brands
[email protected]

Jeff Sonnek
[email protected]

Media Relations Contact:

Penny Kozakos
[email protected]

Cedilla and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

Cedilla and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Cedilla Therapeutics, Inc. (“Cedilla”), a private biotechnology company developing targeted small molecules for the treatment of cancer and other diseases caused by protein dysregulation. The companies will conduct joint research to identify and develop drug candidates directed to a validated, high-value target in oncology that has remained beyond the reach of previous efforts.

HitGen is a world leading biotech company in DNA encoded library-screening, a high throughput compound screening technology, where more than 100,000 times larger libraries can be used than in traditional drug discovery. The platform thus enables faster identification of innovative drug candidates with improved target specificity and enhanced drug-like characteristics.

Pursuant to the terms of the collaboration agreement, HitGen has successfully applied its DEL technology and discovered program compounds that met certain criteria, and Cedilla has received an exclusive license to these compounds as well as associated IP for further development and commercialization. HitGen will be eligible for milestone payments and sublicensing income from Cedilla as the project progresses, in addition to research payments and upfront license fee.

“HitGen is a perfect partner for us in this program, with their cutting-edge DEL platform for screening. Their technology is well established and is now widely used by leading global pharmaceutical and biotech companies,” said Dr. Alexandra Glucksmann, President and CEO of Cedilla. “With HitGen’s support, we are able to accelerate our ongoing efforts to pursue a breadth of high-value oncology targets that have eluded conventional therapeutic modalities. We are very pleased with the program compounds discovered by HitGen to date, are excited to advance these programs forward as we pursue our mission of delivering profound benefit to patients in areas of high unmet need.”

“We are delighted to enter this collaboration with Cedilla, and believe their unique approach to identifying functionally-relevant proteoforms represents a powerful advance in how we think about treating diseases caused by protein dysregulation,” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen. “We believe the collaboration will reinforce the role and reputation of HitGen’s platform in the rapidly developing field of DEL and further demonstrates the power of our DEL platform to discover novel small molecules against a variety of targets. We are working closely with Cedilla scientists and have seen early success towards generating new small-molecule lead compounds for their research programs to help bring transformative medicines to patients.”

About Cedilla Therapeutics, Inc.

Cedilla is a private biotechnology company developing targeted small molecule medicines for the treatment of cancer and other diseases caused by protein dysregulation. The company employs a target-centric approach, focusing on scientifically-validated drivers of disease that have eluded conventional therapeutic modalities. Cedilla identifies functionally-relevant proteoforms, or protein states, creating novel opportunities for therapeutic intervention. For more information, visit www.cedillatx.com.

Investor Contact (Cedilla):

Hannah Deresiewicz

Stern Investor Relations, Inc.

[email protected]


About HitGen Inc.

HitGen is a rapidly growing biotech company with headquarter and main research facility based in Chengdu, China and with a subsidiary in the USA. HitGen has established a platform for small molecule drug discovery research centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs). HitGen’s DELs contain over 500 billion novel, diverse, drug-like small molecule and macrocyclic compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and other solutions.

For more information, please call:


or visit:


For business development:

[email protected]

For investor inquiries:

[email protected]

For media inquiries:

[email protected]

Business Development

[email protected]

KEYWORDS: China Asia Pacific

INDUSTRY KEYWORDS: Health Genetics Research Pharmaceutical Science Biotechnology


Algernon Pharmaceuticals Announces Enrollment of Final Patient in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the final patient has been enrolled in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The aggregate total number of patients enrolled from all countries participating in the study is 168.

The Company recently announced that it would be providing interim data from 75 patients from day 15 of their participation in the study, in the first week of December. Since the treatment period after enrollment is two weeks, with a two-week follow-up thereafter, the interim data readout date has now been moved to the third week of December to ensure that the patients who recently enrolled, can complete their treatment regimen before data is presented.

The Company will update the market shortly on the date when the final data readout will be available.

“I want to thank to the entire AGN team, including all of our clinical trial investigators and their staff, for helping us reach the goal of 100% patient enrollment,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “Our next big step is to see how the preliminary data is trending and we remain hopeful it will show that Ifenprodil is reducing both the severity and duration of a COVID-19 infection. Even with the recent success of certain vaccines in clinical trials, medical doctors need to have effective therapeutic treatment options as well.”

The Company advises that it is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 Coronavirus) at this time.

Phase 2b/3 Study

The Company’s multinational Phase 2b/3 human trial for COVID-19 is entitled, “A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease.”

The trial has begun as a Phase 2b study of an aggregate of 150 patients. With positive preliminary data, the clinical trial will move directly into a Phase 3 trial. The data from the Phase 2b study will determine the number of patients needed to reach statistical significance in the Phase 3 trial. 

Patients are being randomized in a one-to-one manner and will either be treated using an existing standard of care, or standard of care plus Ifenprodil 60 mg (taken as one 20 mg tablet three-times daily) for one arm or standard of care plus Ifenprodil 120 mg (taken as two 20 mg tablets three-times daily) for two weeks.

Over the testing period, doctors will observe whether there is an improvement in a number of secondary endpoints, including mortality, blood oxygen levels, time spent in intensive care and time to mechanical ventilation.

About NP-120 (Ifenprodil)

NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.

The Company believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients. 

About Algernon Pharmaceuticals Inc. 

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.


Christopher J. Moreau
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
[email protected]
[email protected].com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as
“will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement
. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Array Technologies announces a 1GW purchase agreement with RP Construction Services

Partnering with Leading Design-Build Contractor to Bring Advanced Solar Tracker Technology to the Distributed Generation Market

ALBUQUERQUE, N.M., Nov. 30, 2020 (GLOBE NEWSWIRE) — Array Technologies, Inc. (NASDAQ: ARRY) (“Array”) today announced it has entered into an agreement to supply 1GW of DuraTrack® HZ v3 single-axis solar trackers to RP Construction Services, Inc. (“RPCS”). Deliveries under the agreement are expected to commence this December and continue through the end of 2021. RPCS provides design-build services for small and medium-sized ground-mounted solar energy projects across the U.S. and is the leading contractor for solar energy projects under 25 MWs.

“The endorsement of the segment-leading contractor for distributed energy projects underscores both the strength of our product offering and the value our trackers can create for projects of all sizes. The small-utility, municipal, medium-sized commercial and community solar markets are growing rapidly, and collaborating with RPCS to address this segment of the market should further accelerate our growth in the U.S. I am also pleased that this order follows on the Lightsource bp purchase agreement announced earlier this month, making it the second order over 1 GW that we have received in the past 30 days,” said Jim Fusaro, Chief Executive Officer of Array.

“We are incredibly excited about expanding our relationship with Array. They have the best system in the marketplace in terms of ease of installation, reliability, and durability. We have more than tripled the size of our company with their products over the past three years, and we look forward to continuing that growth with this agreement,” said Eb Russell, Chief Executive Officer of RPCS.  

About Array Technologies, Inc.

Array Technologies is a leading global technology company providing tracker solutions and services for utility-scale solar energy projects as one of the world’s largest manufacturers of ground-mounting systems. With efficient installation and terrain flexibility coupled with high reliability, durability, and performance, Array delivers a lower levelized cost of energy. The Company’s focus on innovation, combined with its customer-centric approach, has helped achieve some of the industry’s best returns. Array Technologies is headquartered in the United States with offices in Europe, Central America, and Australia. Contact us at arraytechinc.com or view our LinkedIn page.

About RPCS

RPCS provides turnkey design and installation services for ground-mounted solar energy projects in the U.S. with a focus on the distributed generation market. The Company has completed more than 700 projects, representing 2 GW of generation capacity, since 2015. RPCS combines a team-oriented culture that values all employees with innovative, tech-enabled work practices to deliver projects of all sizes on-spec and on-time. RPCS has approximately 250 employees and maintains offices in California, Mississippi and Texas. Connect with RPCS on LinkedIn or view our website at www.rpcs.com.

Forward Looking Statements

This press release contains forward looking statements. These statements are not historical facts but rather are based on the Company’s current expectations and projections regarding its business, operations and other factors relating thereto. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates” and similar expressions are used to identify these forward looking statements. These statements are only predictions and as such are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual results may differ materially from those in the forward looking statements as a result of a number of factors.

Media Contact:
James McCusker, 203-585-4750
[email protected] 

Investor Relations Contact:
[email protected] 

Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present three posters at European Society of Intensive Care Medicine (ESICM) LIVES 2020, which takes place virtually Dec. 6-9, 2020.

Cidara will highlight analyses from the completed Phase 2 STRIVE trial of rezafungin for treatment of candidemia and/or invasive candidiasis. Rezafungin is a novel once-weekly echinocandin currently in pivotal Phase 3 trials for the treatment and prevention of serious fungal infections. New findings from the STRIVE trial related to intensive care unit (ICU) status will be shared in the poster presentation as follows:

Title: Analysis of the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin: Outcomes by ICU Status and APACHE II Score
Presenter: P. Honoré, CHU Brugmann, Brussels
Session: Infections and Prevention
Format: On-demand

Additional analyses from the STRIVE trial related to geographic region of enrollment and body mass index will be presented. Details are as follows:

Title: Analysis of Outcomes by Geographic Region of Enrollment in STRIVE, the Phase 2 of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis (IC)
Presenter: P. Honoré, CHU Brugmann, Brussels
Session: Infections and Prevention
Format: On-demand

Title: Analysis of the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin: Outcomes by Body Mass Index (BMI)
Presenter: P. Honoré, CHU Brugmann, Brussels 
Session: Infections and Prevention
Format: On-demand

Copies of the posters will be made available on the Publications section of the Cidara website. Additional details can be found in the Abstract Book from ESICM LIVES 2020.

About Rezafungin

Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).

About Cidara Therapeutics

Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.


Brian Ritchie
LifeSci Advisors
(212) 915-2578
[email protected]


Karen O’Shea, Ph.D.
LifeSci Communications
(929) 469-3860
[email protected]

New Research Identifies What Works to Improve Older Driver Safety

SAN FRANCISCO, Nov. 30, 2020 (GLOBE NEWSWIRE) — A newlypublished systematic review and meta-analysis identifies the training activities that have been shown to be effective in improving safety among older drivers. The researchers found that computerized brain exercise training found exclusively in BrainHQ from Posit Science had significant benefits to older drivers’ safety.

There are now more than 44 million drivers over age 65 in the United States. They are second only to newly-licensed drivers in crash rate, and drivers aged 75 and older have the highest death rate due to crashes. There are many different types of interventions deployed to assist older drivers.

The review, published in the journal Accident Analysis and Prevention, evaluated the effects of a variety of interventions on driving performance and auto crash risk. Surprisingly, many of the most commonly-used types of interventions were simply not effective. In particular, classroom or web-delivered lectures on road rules or driving, in-car demonstrations that teach driver and hand positioning, simulator-based training, and on-road training had no significant effect.

The reviewers found only skill-specific interventions – including cognitive training, visual-perceptual training, and physical training – had significant impact on older driver performance.

The reviewers noted that only the speed-of-processing cognitive training (now found exclusively in BrainHQ) significantly reduced at-fault crashes. Other studies of the BrainHQ training also were also cited.

The speed of processing training in BrainHQ progressively challenges users to see things more quickly and with greater accuracy. Such improvements result in more reaction time and a wider field of view (as the brain processes more information at greater speed).

“Older drivers have a lot of experience – they haven’t forgotten how to drive,” said Posit Science CEO Dr. Henry Mahncke. “Giving them drivers education classes again doesn’t help much. The science shows what’s effective is training the brain to be faster and more accurate.”

Independent studies of BrainHQ have shown many positive results for older drivers, including: 38% fewer dangerous driving maneuvers, faster reaction time (equivalent to 22 feet more stopping distance at 55 mph), greater confidence driving in difficult conditions, 48% fewer at-fault crashes, 30% lower overall crash incidence, and maintaining safe driving later in life.

Drivers insured by AAA in many states can get Drivesharp training from BrainHQ through their insurer without charge and can receive a discount on their premium.

ORYX Gaming Partners Enters Swiss Market with mycasino.ch Partnership

Online gaming provider applauds the federal move toward a more modern, regulated betting market

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — ORYX Gaming, a Bragg Gaming Group company (TSXV: BRAG, OTC:BRGGF), is poised to enter the Swiss market for the first time after signing a content deal with leading operator mycasino.ch by Grand Casino Luzern.

The collaboration with mycasino.ch is an important step for ORYX as it continues to implement its growth strategy into regulated jurisdictions across the globe. Grand Casino Luzern is the largest online operator in Switzerland and was the second casino in the country to launch an iGaming offering under the mycasino.ch brand when the market opened in 2019. 

The Swiss regulated online market has quickly gained traction and the latest official figures from the country’s regulator showed that online gaming licensees generated CHF23.5M in the first partial year of being live. Grand Casino Luzern’s brand mycasino.ch generated CHF8.9M in revenues in 2019. 

mycasino.ch marks the first Swiss operator ORYX has partnered with since obtaining its ISO certification earlier this year. Through the deal, Grand Casino Luzern’s customers will soon have access to GAMOMAT’s premium titles with unique in-game features and side-game jackpots that have proven to be extremely popular with players. Top performing titles include Crystal Ball, Fancy Fruits and Ramses Book

ORYX is licensed by the Malta Gaming Authority (MGA) and the Romanian National Gambling Office (ONJN) and is compliant, certified or approved in 18 other major jurisdictions.

, Managing Director of ORYX
Gaming, said: “The Swiss online market is one that we have had an eye on since the new legislation entered into force in 2019 and we are thrilled to finally make our debut.  Grand Casino Luzern makes a perfect partner for us as one of the most established operators in the market with a strong online brand and we look forward to working together to build our presence in the country.” 

, CEO at Grand Casino Luzern, said: “We have had a strong start to our online operations and are constantly looking for fresh and exciting content to enhance the experience for our growing customer base. We’re thrilled to have the opportunity to collaborate with ORYX moving forward. Our main objective is to provide our Swiss players with pure entertainment at the highest level, and we believe ORYX’s portfolio of games can help us achieve just that. GAMOMAT has a broad portfolio of games that appeal to a wide range of players and their features and jackpots are second to none. We are pleased to be the first operator in the country to offer the games through ORYX and are confident that the games will be huge hits with our players.”

About Bragg Gaming Group

Bragg Gaming Group Inc. (TSXV:BRAG, OTC:BRGGF) is an innovative B2B online gaming solution provider.  Leveraging their industry-leading technology, it offers a turnkey solution, including an omni-channel retail, online and mobile iGaming platform, as well as advanced casino content aggregator, sportsbook, lottery, marketing and operational services. Renowned for its rapid and seamless integration, its content aggregator combines casino, slots, live dealer, lottery, virtual sports and instant-win game content from top tier gaming content providers, along with proprietary content, and is fully compliant with major regulated jurisdictions.

Capitalizing on its current portfolio and through targeted acquisitions, Bragg is focused on becoming a leader within the evolving global gaming industry. Learn more at https://www.bragg.games.

For Bragg Gaming Group, contact

Yaniv Spielberg, CSO, Bragg Gaming Group Inc.
[email protected]

For media enquiries or interviews, please contact

Lina Sennevall, Square in the Air
[email protected]

For US investor inquiries, please contact:

Laine Yonker, Edison Group
[email protected]


Tabula Rasa HealthCare Names Celynda G.Tadlock, PharmD, MBA, Chief Client Officer and EVP of Pharmacy Benefit Services

MOORESTOWN, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced the appointment of Celynda G.Tadlock, PharmD, MBA as the Company’s Chief Client Officer and EVP of Pharmacy Benefit Services. Dr. Tadlock will be a member of TRHC’s Executive Committee.

“Selecting Dr. Tadlock to serve as TRHC’s Chief Client Officer will enhance and build upon our strategies and services that bring new innovations to clients and development opportunities for TRHC,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “Dr. Tadlock’s goal will be to create a persistent focus on the client to support needed action to assure client and Company success. Her expertise in pharmacy benefit management (PBM) and services will transition recent acquisitions quickly and efficiently into a combined organization that leverages TRHC’s proprietary science and services.”

Dr. Tadlock recently launched Impera Healthcare Strategies, where she secured agreements in value-based innovations, market access solutions and industry trends. She supported diverse clients, from evidence-based pathway organizations to blockchain consortia to providers to manufacturers, with common interests in managed care. She developed business strategies and created compelling value propositions for products and services in the payer and PBM market place. 

Previously, Dr. Tadlock was Vice President, Clinical Strategy and Pharmacy Experience at Aetna, a CVS Health Company; served as President and Chief Operating Officer, Pharmacy at Coventry; and held executive roles at Express-Scripts and Anthem. At Aetna, she led all aspects of the pharmacy experience serving 15M members, with 225 million prescriptions and $22B drug spend each year. While at Aetna, she also held the role of Vice President, Clinical, Product and Customer Experience and Vice President, Pharmacy Business Development.

“TRHC looks forward to Dr. Tadlock bringing her expertise to assist TRHC in its growth and profitability, its marketing, clinical and product strategies, and industry and trade relations,” said TRHC President and Chief Marketing & Business Development Officer, Orsula V. Knowlton, PharmD, MBA. “We welcome her to TRHC’s Executive Team.”

Dr. Tadlock is President Elect of Georgia Academy of Managed Care Pharmacy (AMCP) and serves on the AMCP Public Policy Committee. She also has been an active member of Pharmaceutical Care Management Association (PCMA) serving on the Operations Committee and leading the Federal and Legal Subcommittees. She frequently is asked to speak at national stage forums relative to managed care, specialty pharmacy and pharmacy benefit management.

Dr. Tadlock received a Doctor of Pharmacy degree from Mercer University in Atlanta, Georgia and a Master of Business Administration degree from Keller Graduate School of Management.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare (TRHC) provides medication safety solutions empowering healthcare professionals to optimize medication regimens and reduce medication-related risk, specifically targeting adverse drug events. Utilizing its proprietary medication decision science technology, MedWise™, TRHC improves patient outcomes, reduces hospitalizations, and lowers healthcare costs. Additionally, TRHC provides an extensive clinical telepharmacy network across the U.S. Its solutions are trusted by health plans and pharmacies nationwide to help drive value-based payment results. For more information, visit TRHC.com.

Forward-Looking Statements

This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 2, 2020, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

TRHC Media Contact

Dianne Semingson
[email protected]
T: (215) 870-0829

TRHC Investor Contact

Frank Sparacino
[email protected]
T: (866) 648-2767